Defective human retinoblastoma protein identified by lack of interaction with the E1A oncoprotein

Marco G. Paggi, Fabio Martelli, Maurizio Fanciulli, Armando Felsani, Salvatore Sciacchitano, Marco Varmi, Tiziana Bruno, Carmine M. Carapella, Aristide Floridi

Research output: Contribution to journalArticle

Abstract

Inactivating mutations of the retinoblastoma susceptibility gene (Rb) are involved in the pathogenesis of hereditary and sporadic retinoblastoma. Alterations in the Rb gene have also been found in several other human tumors occurring with epidemiological incidence higher than that of retinoblastoma. Four human malignant glioma cell lines were examined for abnormalities in the retinoblastoma gene product (pRb), using a procedure based on the interaction of pRb with an in vitro-translated adenovirus E1A oncoprotein. In the CRS-A2 cell line, derived from a glioblastoma multiforme, pRb did not bind with the in vitro-translated E1A protein. Restriction analysis of the CRS-A2 Rb gene and Rb mRNA expression provided patterns that could not be distinguished from the other glioma cell lines. Further investigation revealed the presence of a truncated pRb in the CRS-A2 cell line, due to a nucleotide insertion in the coding sequence at position 2550. In addition, this truncated Rb protein was indetectable in phosphorylated form. The binding assay with the in vitro- translated E1A was also used to study other cell lines with known mutations in the Rb gene. This method, which evaluates the interaction between in vitro-translated E1A and the pRb, is proposed as a rapid screening for detecting functional alterations in the retinoblastoma protein.

Original languageEnglish
Pages (from-to)1098-1104
Number of pages7
JournalCancer Research
Volume54
Issue number4
Publication statusPublished - Feb 15 1994

Fingerprint

Retinoblastoma Genes
Retinoblastoma Protein
Oncogene Proteins
Retinoblastoma
Cell Line
varespladib methyl
Glioma
Mutation
Glioblastoma
Adenoviridae
Nucleotides
Messenger RNA
In Vitro Techniques
Incidence
Neoplasms
Proteins

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Defective human retinoblastoma protein identified by lack of interaction with the E1A oncoprotein. / Paggi, Marco G.; Martelli, Fabio; Fanciulli, Maurizio; Felsani, Armando; Sciacchitano, Salvatore; Varmi, Marco; Bruno, Tiziana; Carapella, Carmine M.; Floridi, Aristide.

In: Cancer Research, Vol. 54, No. 4, 15.02.1994, p. 1098-1104.

Research output: Contribution to journalArticle

Paggi, Marco G. ; Martelli, Fabio ; Fanciulli, Maurizio ; Felsani, Armando ; Sciacchitano, Salvatore ; Varmi, Marco ; Bruno, Tiziana ; Carapella, Carmine M. ; Floridi, Aristide. / Defective human retinoblastoma protein identified by lack of interaction with the E1A oncoprotein. In: Cancer Research. 1994 ; Vol. 54, No. 4. pp. 1098-1104.
@article{5c5df95332f5447ba780f653a1234cdf,
title = "Defective human retinoblastoma protein identified by lack of interaction with the E1A oncoprotein",
abstract = "Inactivating mutations of the retinoblastoma susceptibility gene (Rb) are involved in the pathogenesis of hereditary and sporadic retinoblastoma. Alterations in the Rb gene have also been found in several other human tumors occurring with epidemiological incidence higher than that of retinoblastoma. Four human malignant glioma cell lines were examined for abnormalities in the retinoblastoma gene product (pRb), using a procedure based on the interaction of pRb with an in vitro-translated adenovirus E1A oncoprotein. In the CRS-A2 cell line, derived from a glioblastoma multiforme, pRb did not bind with the in vitro-translated E1A protein. Restriction analysis of the CRS-A2 Rb gene and Rb mRNA expression provided patterns that could not be distinguished from the other glioma cell lines. Further investigation revealed the presence of a truncated pRb in the CRS-A2 cell line, due to a nucleotide insertion in the coding sequence at position 2550. In addition, this truncated Rb protein was indetectable in phosphorylated form. The binding assay with the in vitro- translated E1A was also used to study other cell lines with known mutations in the Rb gene. This method, which evaluates the interaction between in vitro-translated E1A and the pRb, is proposed as a rapid screening for detecting functional alterations in the retinoblastoma protein.",
author = "Paggi, {Marco G.} and Fabio Martelli and Maurizio Fanciulli and Armando Felsani and Salvatore Sciacchitano and Marco Varmi and Tiziana Bruno and Carapella, {Carmine M.} and Aristide Floridi",
year = "1994",
month = "2",
day = "15",
language = "English",
volume = "54",
pages = "1098--1104",
journal = "Journal of Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "4",

}

TY - JOUR

T1 - Defective human retinoblastoma protein identified by lack of interaction with the E1A oncoprotein

AU - Paggi, Marco G.

AU - Martelli, Fabio

AU - Fanciulli, Maurizio

AU - Felsani, Armando

AU - Sciacchitano, Salvatore

AU - Varmi, Marco

AU - Bruno, Tiziana

AU - Carapella, Carmine M.

AU - Floridi, Aristide

PY - 1994/2/15

Y1 - 1994/2/15

N2 - Inactivating mutations of the retinoblastoma susceptibility gene (Rb) are involved in the pathogenesis of hereditary and sporadic retinoblastoma. Alterations in the Rb gene have also been found in several other human tumors occurring with epidemiological incidence higher than that of retinoblastoma. Four human malignant glioma cell lines were examined for abnormalities in the retinoblastoma gene product (pRb), using a procedure based on the interaction of pRb with an in vitro-translated adenovirus E1A oncoprotein. In the CRS-A2 cell line, derived from a glioblastoma multiforme, pRb did not bind with the in vitro-translated E1A protein. Restriction analysis of the CRS-A2 Rb gene and Rb mRNA expression provided patterns that could not be distinguished from the other glioma cell lines. Further investigation revealed the presence of a truncated pRb in the CRS-A2 cell line, due to a nucleotide insertion in the coding sequence at position 2550. In addition, this truncated Rb protein was indetectable in phosphorylated form. The binding assay with the in vitro- translated E1A was also used to study other cell lines with known mutations in the Rb gene. This method, which evaluates the interaction between in vitro-translated E1A and the pRb, is proposed as a rapid screening for detecting functional alterations in the retinoblastoma protein.

AB - Inactivating mutations of the retinoblastoma susceptibility gene (Rb) are involved in the pathogenesis of hereditary and sporadic retinoblastoma. Alterations in the Rb gene have also been found in several other human tumors occurring with epidemiological incidence higher than that of retinoblastoma. Four human malignant glioma cell lines were examined for abnormalities in the retinoblastoma gene product (pRb), using a procedure based on the interaction of pRb with an in vitro-translated adenovirus E1A oncoprotein. In the CRS-A2 cell line, derived from a glioblastoma multiforme, pRb did not bind with the in vitro-translated E1A protein. Restriction analysis of the CRS-A2 Rb gene and Rb mRNA expression provided patterns that could not be distinguished from the other glioma cell lines. Further investigation revealed the presence of a truncated pRb in the CRS-A2 cell line, due to a nucleotide insertion in the coding sequence at position 2550. In addition, this truncated Rb protein was indetectable in phosphorylated form. The binding assay with the in vitro- translated E1A was also used to study other cell lines with known mutations in the Rb gene. This method, which evaluates the interaction between in vitro-translated E1A and the pRb, is proposed as a rapid screening for detecting functional alterations in the retinoblastoma protein.

UR - http://www.scopus.com/inward/record.url?scp=0028353293&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028353293&partnerID=8YFLogxK

M3 - Article

C2 - 8313367

AN - SCOPUS:0028353293

VL - 54

SP - 1098

EP - 1104

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0008-5472

IS - 4

ER -